The sample types eligible for analysis with its ClonoSIGHT™minimal residual disease (MRD) test for leukemia and lymphoma from Sequenta Inc, South San Francisco, have been expanded to include formalin-fixed, paraffin-embedded (FFPE) tissue and bone marrow aspirate slides.
This advancement allows the test to be performed on the diagnostic samples most commonly available from pathology labs.
The test uses the proprietary LymphoSIGHT™ platform, which works by sequencing unique DNA signatures present in immune cells, to identify cancer cell clones in diagnostic samples and then detect and track the resurgence of these cells after treatment.
The sequencing-based readout provides quantitative results that can be directly interpreted by oncologists. Testing for MRD can help determine whether treatment has been successful, provide important information about patient prognosis, and help guide additional treatment decisions.
The company says its ClonoSIGHT test is the first clinically actionable sequencing-based test for MRD in leukemia and lymphoma, and notes that it has been shown to offer unprecedented sensitivity for the detection of residual cancer cells in bone marrow or blood. The LymphoSIGHT platform can detect malignant subpopulations of cells even when they are present at levels as low as one cell per million white blood cells. Test results are generated in 7 days using Sequenta’s CLIA-certified lab.
[Source: Sequenta]
